Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Opium (Opioid) Addiction-Pipeline Review, H1 2015

Opium (Opioid) Addiction-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Opium (Opioid) Addiction-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Opium (Opioid) Addiction-Pipeline Review, H1 2015', provides an overview of the Opium (Opioid) Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Opium (Opioid) Addiction Overview 9

Therapeutics Development 10

Pipeline Products for Opium (Opioid) Addiction-Overview 10

Pipeline Products for Opium (Opioid) Addiction-Comparative Analysis 11

Opium (Opioid) Addiction-Therapeutics under Development by Companies 12

Opium (Opioid) Addiction-Therapeutics under Investigation by Universities/Institutes 13

Opium (Opioid) Addiction-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Opium (Opioid) Addiction-Products under Development by Companies 17

Opium (Opioid) Addiction-Products under Investigation by Universities/Institutes 19

Opium (Opioid) Addiction-Companies Involved in Therapeutics Development 20

Acura Pharmaceuticals, Inc. 20

Alkermes Plc 21

BioDelivery Sciences International, Inc. 22

Camurus AB 23

Celtic Pharmaceutical Holdings L.P. 24

D&A Pharma SAS 25

Foresee Pharmaceuticals, LLC 26

Heron Therapeutics, Inc. 27

Indivior PLC 28

INSYS Therapeutics, Inc. 29

Omeros Corporation 30

Pfizer Inc. 31

Relmada Therapeutics, Inc. 32

Titan Pharmaceuticals, Inc. 33

Zynerba Pharmaceuticals, Inc. 34

Opium (Opioid) Addiction-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Combination Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Buprenorphine Hemiadipate Hydrochloride-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

buprenorphine hydrochloride-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

buprenorphine hydrochloride-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

buprenorphine hydrochloride-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

buprenorphine hydrochloride depot-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

buprenorphine hydrochloride ER-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

buprenorphine hydrochloride long acting-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

buprenorphine hydrochloride SR-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

cannabidiol-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

cannabidiol-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

FP-004-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

MAL-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

methadone IR-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

naltrexone-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

naltrexone-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

OMS-405-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

OMS-527-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

PF-5006739-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

samidorphan-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

TA-CD-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Vaccine for Opium Addiction-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Opium (Opioid) Addiction-Recent Pipeline Updates 73

Opium (Opioid) Addiction-Dormant Projects 77

Opium (Opioid) Addiction-Discontinued Products 78

Opium (Opioid) Addiction-Product Development Milestones 79

Featured News & Press Releases 79

Apr 02, 2015: Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market 79

Mar 24, 2015: Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine 80

Feb 24, 2015: Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine 80

Jan 06, 2015: Titan Pharmaceuticals to Present at 8th Annual OneMedForum 80

Dec 01, 2014: Titan Pharmaceuticals to Present at LD Micro Conference 81

Nov 20, 2014: Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence 81

Sep 23, 2014: Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence 82

Jul 21, 2014: Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence 83

Apr 30, 2014: Braeburn Pharmaceuticals To Initiate New Clinical Study For Probuphine Following Clear Guidance From FDA 83

Dec 23, 2013: Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application 84

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2015 10

Number of Products under Development for Opium (Opioid) Addiction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Opium (Opioid) Addiction-Pipeline by Acura Pharmaceuticals, Inc., H1 2015 20

Opium (Opioid) Addiction-Pipeline by Alkermes Plc, H1 2015 21

Opium (Opioid) Addiction-Pipeline by BioDelivery Sciences International, Inc., H1 2015 22

Opium (Opioid) Addiction-Pipeline by Camurus AB, H1 2015 23

Opium (Opioid) Addiction-Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015 24

Opium (Opioid) Addiction-Pipeline by D&A Pharma SAS, H1 2015 25

Opium (Opioid) Addiction-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 26

Opium (Opioid) Addiction-Pipeline by Heron Therapeutics, Inc., H1 2015 27

Opium (Opioid) Addiction-Pipeline by Indivior PLC, H1 2015 28

Opium (Opioid) Addiction-Pipeline by INSYS Therapeutics, Inc., H1 2015 29

Opium (Opioid) Addiction-Pipeline by Omeros Corporation, H1 2015 30

Opium (Opioid) Addiction-Pipeline by Pfizer Inc., H1 2015 31

Opium (Opioid) Addiction-Pipeline by Relmada Therapeutics, Inc., H1 2015 32

Opium (Opioid) Addiction-Pipeline by Titan Pharmaceuticals, Inc., H1 2015 33

Opium (Opioid) Addiction-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 34

Assessment by Monotherapy Products, H1 2015 35

Assessment by Combination Products, H1 2015 36

Number of Products by Stage and Target, H1 2015 38

Number of Products by Stage and Mechanism of Action, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Opium (Opioid) Addiction Therapeutics-Recent Pipeline Updates, H1 2015 73

Opium (Opioid) Addiction-Dormant Projects, H1 2015 77

Opium (Opioid) Addiction-Discontinued Products, H1 2015 78

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H1 2015 10

Number of Products under Development for Opium (Opioid) Addiction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Top 10 Targets, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 38

Number of Products by Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acura Pharmaceuticals, Inc. 20

Alkermes Plc 21

BioDelivery Sciences International, Inc. 22

Camurus AB 23

Celtic Pharmaceutical Holdings L.P. 24

D&A Pharma SAS 25

Foresee Pharmaceuticals, LLC 26

Heron Therapeutics, Inc. 27

Indivior PLC 28

INSYS Therapeutics, Inc. 29

Omeros Corporation 30

Pfizer Inc. 31

Relmada Therapeutics, Inc. 32

Titan Pharmaceuticals, Inc. 33

Opium (Opioid) Addiction Therapeutic Products under Development, Key Players in Opium (Opioid) Addiction Therapeutics, Opium (Opioid) Addiction Pipeline Overview, Opium (Opioid) Addiction Pipeline, Opium (Opioid) Addiction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com